New drug shows promise for treating blood cancer

Updated at: June 12, 2026 at 01:30 AM

As of June 2026, medical breakthroughs presented at the EHA and ASCO congresses are transforming blood cancer care.

nounbreakthrough

verbtransform

Recent clinical trials highlight two major areas of progress: improved clinical efficacy and more practical treatment delivery.

nounefficacy

In terms of survival, new drug combinations are showing great potential.

nounsurvival

nounpotential

Beyond new drugs, experts are focusing on making treatments more accessible.

adjectiveaccessible

A key development is the shift toward outpatient care for advanced immunotherapies.

adjectiveoutpatient

For instance, the EPCORE NHL-6 trial confirmed that epcoritamab can be safely administered outside of a hospital, allowing community oncologists to treat patients without requiring long hospital stays.

verbadminister

Furthermore, researchers are pushing for chemotherapy-free options, such as fixed-duration venetoclax combinations, to reduce treatment toxicity.

nountoxicity

These advancements reflect a significant shift in oncology, prioritizing both the effectiveness of new therapies and the ease of access for patients globally.

adverbglobally

🎉

End of article

You read 8 focus sentences.

Challenge Mode

Comprehension Questions

What is the primary significance of the EPCORE NHL-6 trial finding?

It confirmed that Selinexor can replace all existing immunotherapy drugs.

It demonstrated that epcoritamab can be safely administered in an outpatient setting.

It proved that chemotherapy is entirely obsolete for all blood cancers.

Reveal Answer

✓

Correct Choice

It demonstrated that epcoritamab can be safely administered in an outpatient setting.

What does the SENTRY trial suggest about the combination of Selinexor and Ruxolitinib?

It is mainly used to reduce the cost of hospital stays.

It is the standard treatment for diffuse large B-cell lymphoma.

It may significantly improve overall survival for JAK inhibitor-naïve myelofibrosis patients.

Reveal Answer

✓

Correct Choice

It may significantly improve overall survival for JAK inhibitor-naïve myelofibrosis patients.

What is a major challenge currently facing CAR-T cell therapy access?

Only a small percentage of eligible patients currently receive the treatment.

The treatment is only effective for children.

There are no FDA-approved CAR-T therapies available yet.

Reveal Answer

✓

Correct Choice

Only a small percentage of eligible patients currently receive the treatment.

What is the benefit of 'chemotherapy-free' alternatives mentioned in the text?

They are always cheaper than traditional chemoimmunotherapy.

They completely eliminate the need for physician monitoring.

They help patients avoid the toxicity associated with traditional chemoimmunotherapy.

Reveal Answer

✓

Correct Choice

They help patients avoid the toxicity associated with traditional chemoimmunotherapy.

Which trial showed that polatuzumab vedotin improves outcomes for lymphoma patients?

The EPCORE NHL-6 trial.

The POLARGO trial.

The SENTRY trial.

Reveal Answer

✓

Correct Choice

The POLARGO trial.

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App Store Google Play